Amryt Pharma inks distribution agreement for Lojuxta®
With 500 employees and sales exceeding €200m in 2020, Swixx is one of the fastest-growing dedicated agents for biopharma and self-medication innovative companies across CEE.
Specifically, Amryt, a commercial stage pharmaceutical firm, has now appointed Swixx as exclusive distributor of its therapeutic Lojuxta® (lomitapide) across 17 jurisdictions in CEE.
Lojuxta® is a prescription medicine used alongside diet and other lipid-lowering treatments, including low-density lipoprotein (LDL) apheresis where available, in adults with homozygous familial hypercholesterolaemia (HoFH), a rare life-threatening condition.
Today’s agreement follows Amryt’s appointment of Swixx in June 2020 as exclusive distributor of its leptin replacement therapy Myalepta® (metreleptin) across CEE.
Shares in Amryt Pharma have increased in value by over 20% since September 2020 and opened up 1% today at 197p.
The agreement represents new territories for the Group to further accelerate its revenue growth, augmenting sales already being generated through its existing salesforce in the EU.
Under the agreement, Swixx will distribute Lojuxta® from October 2020 in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Poland, Romania, Serbia and Slovakia. In addition, from January 2021, Swixx will expand its distribution of Lojuxta® into Czech Republic, Hungary and Slovenia.
“Lomitapide is an important contributor to Amryt’s commercial performance and growth and today’s announcement demonstrates the progress we are making in expanding lomitapide’s reach in existing and new territories,” said Joe Wiley, CEO of Amryt Pharma.
He added, “Also, we are excited to grow and consolidate our existing partnership with Swixx who currently distribute metreleptin exclusively across the CEE territories.”
Lojuxta® is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for HoFH in the US, Canada, Columbia, Argentina and Japan. The product trades under the trade name Juxtapid® and in the EU under the trade name Lojuxta®.
Follow News & Updates from Amryt Pharma here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.